News coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CareDx earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.7545890719648 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several research analysts have issued reports on CDNA shares. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of CareDx in a research report on Wednesday, January 31st. Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Wednesday, January 10th. Finally, ValuEngine upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. CareDx currently has a consensus rating of “Buy” and an average price target of $8.65.
CareDx stock opened at $6.06 on Thursday. The company has a debt-to-equity ratio of -124.53, a current ratio of 0.55 and a quick ratio of 0.35. The stock has a market cap of $163.04, a P/E ratio of -3.35 and a beta of 0.72. CareDx has a 12-month low of $0.76 and a 12-month high of $7.98.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.